Invention Grant
- Patent Title: Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
-
Application No.: US16591175Application Date: 2019-10-02
-
Publication No.: US11319362B2Publication Date: 2022-05-03
- Inventor: Po-Ying Chan-Hui , Katherine Doores , Michael Huber , Stephen Kaminsky , Steven Frey , Ole Olsen , Jennifer Mitcham , Matthew Moyle , Sanjay K. Phogat , Dennis R. Burton , Laura Marjorie Walker , Pascal Raymond Georges Poignard , Wayne Koff , Melissa Danielle De Jean De St. Marcel Simek-Lemos
- Applicant: THERACLONE SCIENCES, INC. , THE SCRIPPS RESEARCH INSTITUTE , INTERNATIONAL AIDS VACCINE INITIATIVE
- Applicant Address: US WA Seattle; US CA La Jolla; US NY New York
- Assignee: THERACLONE SCIENCES, INC.,THE SCRIPPS RESEARCH INSTITUTE,INTERNATIONAL AIDS VACCINE INITIATIVE
- Current Assignee: THERACLONE SCIENCES, INC.,THE SCRIPPS RESEARCH INSTITUTE,INTERNATIONAL AIDS VACCINE INITIATIVE
- Current Assignee Address: US WA Seattle; US CA La Jolla; US NY New York
- Agency: Duane Morris LLP
- Agent Thomas J. Kowalski; Deborah L. Lu
- Main IPC: C07K16/10
- IPC: C07K16/10 ; A61P31/18 ; A61K39/21 ; A61K39/00

Abstract:
The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
Public/Granted literature
- US20200024330A1 BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODY Public/Granted day:2020-01-23
Information query